<DOC>
	<DOCNO>NCT02461706</DOCNO>
	<brief_summary>The main goal study provide treatment cannabidiol ( CBD ) child drug resistant epilepsy Physician Expanded Access Investigation New Drug protocol . As controlled therapeutic use CBD child novel , primary objective study evaluate safety efficacy CBD administer adjunctive therapy child exhaust majority FDA approve antiepileptic drug treatment option .</brief_summary>
	<brief_title>Treatment Drug Resistant Epilepsy</brief_title>
	<detailed_description>Fifty , ( 50 ) child provide CBD part Principal Investigator 's Physician Expanded Access IND . CBD administer adjunct current antiepileptic drug . After screen visit , 4 week baseline period follow seizure record seizure diary give patient time . The patient clinically evaluated baseline , month three month every three month thereafter . For first week study initiation , patient call day 3 review change condition day 7 review change condition determine whether increase dosing require . Subsequently , patient call week titration period review change condition determine whether increase dosing require . Maximal dose titration achieve patient within 5 week . In order ensure safe use high dos , patient receive 600 mg daily CBD evaluate least monthly achieve steady state final fix maintenance dose . The investigator available telephone email throughout initial four month study visit .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>history trial least four drug , include one trial combination two concomitant drug , without successful seizure control . Vagal nerve stimulation : VNS must stable setting minimum 1 month , RNS deep brain stimulation , ketogenic diet consider equivalent drug trial must stable ratio minimum 3 month . antiepileptic drug stable dos minimum 4 week prior enrollment . 4 clinically countable seizure per month : Seizure history include document history generalize seizure ( drop attack , atonic , tonicclonic and/or myoclonic ) , focal seizure without loss consciousness motor component , focal seizure loss consciousness , focal seizure secondary generalization , Use CBD base product within previous 30 day . Initiation felbamate within 6 month . Allergy CBD cannabinoid . Unable comply study visits/requirements . Diagnosis Dravet Syndrome LennoxGastaut syndrome exclude completely trial . Cannabidiol contraindicate pregnancy . Female subject pregnant exclude study . If female subject able become pregnant , give serum pregnancy test entry study . Female subject inform become pregnant take cannabidiol . Female subject must tell investigator consult obstetrician maternalfetal specialist become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug resistant epilepsy</keyword>
</DOC>